Table Graph
   

antiviral and associated therapy - versus placebo - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.46 [0.03, 8.02]< 10%1 study (1/-)70.0 %NAnot evaluable crucial-
deaths 0.12 [0.01, 2.36]< 10%1 study (5/-)91.6 %NAnot evaluable crucial-
clinical deterioration 0.75 [0.30, 1.84]< 10%2 studies (2/-)73.8 %highnot evaluable lowimportant-
clinical improvement 0.81 [0.52, 1.27]> 10%1 study (1/-)18.1 %NAnot evaluable important-
clinical improvement (7-day) 0.90 [0.77, 1.06]> 10%1 study (2/-)9.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.40 [0.91, 2.15]> 10%1 study (2/-)93.8 %NAnot evaluable important-
hospital discharge 1.20 [0.73, 1.98]> 10%1 study (3/-)76.3 %NAnot evaluable important-
hospitalization 0.12 [0.01, 2.26]< 10%1 study (1/-)92.0 %NAnot evaluable important-
mechanical ventilation 0.20 [0.00, 8.69]< 10%1 study (2/-)79.4 %NAnot evaluable important-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (3/-)17.3 %NAnot evaluable important-
viral clearance (time to event analysis only) 1.58 [0.31, 8.10]> 183%2 studies (2/-)70.6 %lownot evaluable highimportant-
viral clearance by day 14 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 7 0.91 [0.77, 1.08]> 10%2 studies (3/-)13.7 %lownot evaluable highimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (2/-)57.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 2.80 [0.14, 56.95]< 10%1 study (2/-)25.4 %NAnot evaluable important-
adverse events 4.78 [0.26, 87.65]< 190%2 studies (4/-)14.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons